The HIV prevention world has changed dramatically in the more than 10 years since the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ Truvada as pre-exposure prophylaxis (PrEP) in July 2012.
Following the discovery that Truvada can pose renal and bone density problems in some individuals (which, thankfully, go away after the medication is discontinued), the FDA approved Gilead’s more kidney-and-bone-friendly Descovy as PrEP in October 2019. While Truvada is currently available as a generic equivalent, Descovy is still under patent…
